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Abstract. Haiti has the highest burden of rabies in the Western hemisphere, with 130 estimated annual deaths.
We present the cost-effectiveness evaluation of an integrated bite case management program combining community
bite investigations and passive animal rabies surveillance, using a governmental perspective. The Haiti Animal
Rabies Surveillance Program (HARSP) was first implemented in three communes of the West Department, Haiti.
Our evaluation encompassed all individuals exposed to rabies in the study area (N = 2,289) in 2014–2015. Costs
(2014 U.S. dollars) included diagnostic laboratory development, training of surveillance officers, operational costs,
and postexposure prophylaxis (PEP). We used estimated deaths averted and years of life gained (YLG) from
prevented rabies as health outcomes. HARSP had higher overall costs (range: $39,568–$80,290) than the no-bite-
case-management (NBCM) scenario ($15,988–$26,976), partly from an increased number of bite victims receiving
PEP. But HARSP had better health outcomes than NBCM, with estimated 11 additional annual averted deaths in
2014 and nine in 2015, and 654 additional YLG in 2014 and 535 in 2015. Overall, HARSP was more cost-effective
(US$ per death averted) than NBCM (2014, HARSP: $2,891–$4,735, NBCM: $5,980–$8,453; 2015, HARSP: $3,534–
$7,171, NBCM: $7,298–$12,284). HARSP offers an effective human rabies prevention solution for countries trans-
itioning from reactive to preventive strategies, such as comprehensive dog vaccination.
INTRODUCTION
Rabies is a viral zoonosis that imposes a substantial
burden in many developing countries, with approximately
59,000 annual deaths globally.1–3 Rabies transmission
occurs in more than 150 countries and affects roughly
half of the world’s population. Human rabies is almost
certainly fatal once clinical symptoms appear, but can
be prevented if the bite victim is promptly administered
postexposure prophylaxis (PEP).4 There are numerous
rabies reservoir species globally; however, the vast major-
ity of human rabies deaths are due to the virus variant
enzootic in domesticated dog populations. Controlling
dog rabies substantially reduces human exposure to the
virus,1,5 which can be accomplished through periodical
mass dog vaccination.1,6,7 But the costs of vaccination
campaigns can be substantial.8 The Republic of Haiti has
the highest human rabies burden in the Western Hemi-
sphere,9,10 with an estimated 130 annual human deaths.2
As in other developing countries,1,2,8,11–16 many human and
dog rabies cases are not recognized and are not reported
to health authorities, thus limiting rabies awareness, fund-
ing, and prevention efforts.10 Dog bite victims often do not
present to health-care facilities and PEP supplies may be
limited.2,17,18 Budget constraints have resulted in limited pas-
sive rabies surveillance, inadequate laboratory capacity, few
trained professionals, and NBCM (thus, all dog bites are
treatedas suspected rabies exposures).10,17,19 Government-
sponsored dog vaccination campaigns in Haiti have not
been conducted to the frequency and intensity required for
rabies elimination.19
In collaboration with the U.S. Centers for Disease Con-
trol and Prevention (CDC), the Haitian government initi-
ated in 2013 the Haiti Animal Rabies Surveillance Program
(HARSP), a form of integrated bite case management com-
bining community bite investigations and passive animal
rabies investigations to provide tailored rabies risk assess-
ments for persons potentially exposed to the rabies virus.10
HARSP was established in three stages, beginning in 2011–
2012 with the establishment of an animal rabies diagnostic
facility. Stage 2 (2012–2013) involved the training of animal
surveillance officers, including animal rabies surveillance,
bite investigations, and use of equipment for safe and
humane animal capture. The final stage was the implemen-
tation of the program. Investigations to locate biting dogs
were triggered by a bite victim presenting for medical treat-
ment in sentinel and nonsentinel hospitals or by reporting
of suspect animals from the community. Offending animals
were either euthanized or confined for observation, and
potential bite victims were traced, advised to seek PEP,
and referred to health-care facilities. In the first 2 years of
operation, HARSP established a much higher dog rabies
burden than previously recorded (∼18-fold increase in
reporting of rabid animals), and averted numerous deaths
from human rabies (∼3-fold increase in PEP of people with
probable rabies exposure).9,10,17
While comprehensive dog vaccination is the ideal for
rabies prevention and control, integrated bite case manage-
ment programs may offer an efficient rabies-prevention and
control solution for countries with high risk of rabies trans-
mission and insufficient dog rabies vaccination coverage.
Dog bite investigations allow removing rabid dogs from
the community thus reducing potential exposures, and
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encouraging bite victims to seek appropriate medical care.
By establishing reliable case definitions, bite victims of neg-
ative dogs can avoid unnecessary PEP. These programs also
improve surveillance data, which can be used to assess dis-
ease burden, evaluate intervention programs and strategies,
inform policy-makers, and focus on disease elimination.8
Herein, we present the results from a cost-effectiveness
analysis of the implementation of an integrated bite case
management program, HARSP, in Haiti for the 2 years,
2014 and 2015, from the perspective of the government.
We limit our analysis to the locations in which HARSP
was first implemented: the West Department communes
of Pétionville, Carrefour, and Croix-des-Bouquets (Figure 1).
These communities were chosen based on available infra-
structure, such as roads and medical care facilities, and
represent the range of socioeconomic conditions that pre-
vail in Haiti. They are largely urban and probably have
higher dog vaccination rates than most of the country due
to recent annual dog vaccination campaigns.10 The results
from this evaluation are intended to provide public and gov-
ernment entities affected by dog rabies with evidence to
inform policy decisions about program replication.
MATERIALS AND METHODS
Model.HARSP implementation began in 2013 in Pétionville
and was fully operational in all three communes by 2014.
Using epidemiological and cost data from 2014 to 2015, we
estimated the annual costs and effectiveness of HARSP
from a governmental perspective. We developed a user-
friendly spreadsheet (Supplemental File 1), where further
details about calculations are provided. We estimated the
costs and effectiveness of four alternative ways of imple-
menting human rabies prevention programs (Table 1). The
four scenarios assessed were 1) No bite case management
(NBCM), that is, the medical treatment of dog bite victims
that report to the health system with suspected rabies
exposures (the situation in Haiti before the implementation
of HARSP); 2) HARSP intervention, including animal rabies
surveillance, bite investigations, and medical treatment of
bite victims that report to the health system, including those
potential victims advised to seek PEP during community
bite investigations; 3) HARSP recommended (HARSPr), the
hypothetical situation in which recommendations for rabies
prevention and PEP treatment by HARSP are fully adhered;
and 4) World Health Organization recommended (WHOr),
the hypothetical situation in which all bite victims that seek
medical treatment receive PEP according to the WHO
recommendations.8 The latter two scenarios represent the
potential for improvement of HARSP and NBCM, respec-
tively, because they illustrate the results of rabies preven-
tion and control if people strictly followed recommended
guidelines. We considered the same self-directed bite vic-
tims’ health-care-seeking behavior in the four scenarios;
however, in the HARSP scenarios, we also added the pro-
portion of bite victims that did not present to the health-
care system initially but were encouraged to seek treatment
as a result of dog bite investigations in their communities.
We compared all four scenarios based on the number
of rabies exposed persons (n2014 = 837; n2015 = 1,373), as
assessed by HARSP during 2014 and 2015.
Epidemiologic data. Epidemiologic data included total
human exposures, type of exposure,8 average number of
PEP vaccines administered, and estimated rabies cases.
The baseline rabies-exposure data were based on the
results of HARSP animal rabies investigations. HARSP and
HARSPr were the only scenarios in which information about
categories of dog rabies exposure (confirmed, probable,
suspected, negative) would be known because of the ani-
mal assessment component. Bite victims in NBCM and
WHOr would have been treated as having suspected rabies
exposures since no further investigation or classification of
the offending animal would have been pursued (Table 2).
However, not all bite victims who sought health care in the
NBCM initiated PEP.
Cost data. Cost inputs included diagnostic laboratory
development (start-up and maintenance), training of surveil-
lance officers, operational costs (bite investigations, rabies
surveillance, laboratory diagnosis), and also costs associ-
ated with rabies exposures and treatment of suspected rabies
exposures. All costs were adjusted to 2014 dollars using
gross domestic product implicit price deflators21 and program
FIGURE 1. Location of the intervention and implementation of the
rabies control program, Haiti, 2014–2015. (A) Map of the region
where the Haiti Animal Rabies Surveillance Program was imple-
mented. The program was initiated in three communes of the West
Department (Ouest), Pétionville (population = 359,615; 89% urban),
Carrefour (population = 487,980; 96% urban), and Croix-des-
Bouquets (population = 238,222; 47% urban).32 (B) A rabies control
officer uses food and a control pole to capture a free-roaming dog
for a rabies assessment. HARSP had an active bite investigation
component which helped identify an additional 40% bite victims.
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costs were annualized. Equipment for diagnostics included
fluorescent microscope, incubator, freezer (solar), and fume
hood (useful life: 5 years for all, except microscope: 10 years).
For capital costs, we used the equivalent annual cost for
the capital outlay considering that the resale value is zero.
For the vehicles and most investments we considered a
useful life of 5 years (details in Supplemental File 2, Appen-
dix A). The costs of training in HARSP and HARSPr were
prorated through 5 years (with no adjustment for inflation or
discounting since the investment was on the first year).
We used previous studies to obtain the costs per dose
of human rabies vaccine,12 unit costs of cold-chain (based
on estimates of cold-chain costs for a measles vaccine in
Haiti),22 and costs per outpatient visit based on WHO choice
estimates for a public health facility in Haiti.23 Because we
had no specific cost data for surveillance and diagnostics
in Haiti prior to HARSP, we estimated the following values,
based on the rabies diagnostic and surveillance activities,
personnel, and equipment in place before the implementa-
tion of HARSP: 1) for the diagnostic facility, we considered
a −20°C freezer, light microscope, 60% of the costs of
equipment maintenance (compared with HARSP), $200 in
reagents, 10% of HARSP costs for office supplies, same
personnel costs, same office rental and utilities; 2) no costs
of training personnel, and 3) 10% of HARSP costs in sur-
veillance. Last, we estimated that the costs of the rabies
TABLE 2
Baseline epidemiological data for the evaluation of the HARSP, Pétion-Ville, Carrefour, and Croix-des-Bouquets, West Department, Haiti,
2014–2015
Value
Item Units 2014 2015 Source
Study population* N 837 1,373 HARSP
Human exposures to rabies HARSP
Confirmed N 33 29
Probable N 59 39
Suspected N 166 177
Negative N 579 1,128
Type of exposure (share)†
Category I % 0% 0% Estimate
Category II % 18% 16% Wallace and others10
Category III (needs to add to 100%) % 82% 84% HARSP
Average PEP vaccines administered (HARSP) HARSP
Confirmed N 4.3 4.3
Probable N 2.4 2.4
Suspected N 3 3
Negative N 2.7 2.7
Age distribution of rabies cases and exposures Cleaveland and others11
0–4 % 9 9
5–9 % 18 18
10–14 % 18 18
> 15 % 55 55
Probability that suspected rabid dog had rabies infection % 6.3 6.3 HARSP
Probability of acquiring rabies if exposed with no PEP‡ % 19 19 Shim and others20
HARSP = Haiti Animal Rabies Surveillance Program; PEP = postexposure prophylaxis; RIG = rabies immunoglobulin; WHO = World Health Organization. Most field data were collected by
HARSP officers. Data correspond to 2014 and 2015; additional epidemiological data are shown in the Supplemental File 2, Appendix A.
*The study population included all persons who were potentially exposed to rabies and were in contact with HARSP or local health clinics.
†The types of contact were defined following WHO PEP recommendations, and are defined as follows8: Category I: touching or feeding animals, licks on the skin. Category II: nibbling of
uncovered skin, minor scratches or abrasions without bleeding, licks on broken skin. Category III: single or multiple transdermal bites or scratches, contamination of mucous membrane with
saliva from licks, exposure to bat bites or scratches. Category I requires no treatment, Category II requires immediate vaccination, and Category III requires immediate vaccination and RIG.
‡The probability of acquiring rabies if exposed and not given PEP varies depending on several factors, including the type of exposure, anatomic site of the exposure, and severity. Another
study in Tanzania,16 estimated that 14% of patients would have died had they not received PEP.
TABLE 1
Evaluation of the HARSP and three comparison scenarios for rabies prevention under the same baseline conditions, Pétionville, Carrefour,
and Croix-des-Bouquets communes, West Department, Haiti, 2014–2015
Scenario Description
NBCM Rabies prevention and control corresponds to the situation before HARSP was implemented, that is, passive surveillance,
limited diagnostic capabilities, few trained health-care workers, and NBCM (i.e., treatment of dog bite victims that report
to the health system as suspected rabies exposures)
HARSP HARSP is a community-based animal rabies surveillance program with two components: active community bite investigation
and passive animal rabies investigation. It includes updating laboratory and rabies surveillance capabilities.
HARSPr* Activities related to rabies surveillance, rabies diagnostics, dog investigations, and treatment of suspected rabies exposures
correspond to the best possible implementation of the HARSP program, strictly adhering to suggested guidelines
and recommendations for the program.
WHOr* Activities related to rabies surveillance, rabies diagnostics, dog investigations, and treatment of suspected rabies exposures
correspond to the situation in Haiti NBCM, but all bite victims that seek medical treatment receive PEP according to
WHO guidelines and recommendations for rabies treatment.
HARSP = Haiti Animal Rabies Surveillance Program; HARSPs = HARSP recommended; NBCM = no bite case management; PEP = postexposure prophylaxis; WHO = World Health Organi-
zation; WHOr = WHO recommended.
*Scenarios HARSPr and WHOr represent the potential for improvement, if guidelines and recommendations were strictly followed, of HARSP and NBCM (no HARSP).
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surveillance and diagnostics for WHOr (scenario 4) were the
same as those for NBCM (scenario 1); these scenarios only
differed in rabies exposures treated and PEP compliance.
None of these two scenarios (NBCM and WHOr) had a
training component for active animal surveillance. The
costs of the rabies surveillance, diagnostic, and training for
HARSP and HARSPr were equivalent. Table 3 shows the
costs of treating people with suspected rabies exposure,
including PEP vaccines, rabies immunoglobulin (RIG), and
outpatient visits, and basic cost input to estimate the costs
of surveillance, diagnostics, and training (Supplemental File 2,
Appendix A).
Health and economic outcomes. Per the four program-
matic scenarios (NBCM, HARSP, HARSPr, WHOr), we esti-
mated health outcomes as the total fatal human rabies
infections and years of life lost (YLL) to premature death
from rabies infection. Health outcomes were derived for
each scenario from the estimated human rabies infections,
calculated from the proportion of people bitten by a rabid
dog (confirmed, probable, or suspected rabies), the probabil-
ity that the bite victim was exposed to rabies, and the proba-
bility of acquiring rabies if exposed with no PEP. To estimate
the number of fatal rabies infections, we combined the esti-
mated human rabies infections with the probability that a bite
victim sought medical care, including bite victims that were
found in community bite investigations (Supplemental File 2,
Appendix A). We assumed that patients who received PEP
did not develop rabies, independent of overall compliance.
For each scenario, we estimated cost outcomes as the total
PEP vaccine doses administered and economic costs of
the intervention. For patients with potential rabies exposure
in the NBCM scenario, we considered the same compliance
with PEP treatment as those who were exposed to sus-
pected rabid dogs in HARSP, and the same criteria applied
to RIG. We considered one outpatient visit per vaccine dose
administration; the total estimated visits per patient were
thus a function of treatment compliance. The acute phase of
rabies typically lasts between 2 and 10 days; once symp-
toms appear the disease is almost always fatal.24 Few epi-
sodes of rabies, if any, are hospitalized.2 Furthermore, only
a small proportion of rabies cases are identified through
hospital-based reporting in Haiti.19 We thus excluded
hospitalization costs. All outcomes were estimated based
on the sample of patients who were reported to HARSP in
2014 and 2015 from any source. We summarized the cost-
effectiveness of each scenario as the average cost per
human rabies death averted and average cost per life year
gained. Further details about calculations are shown in Sup-
plemental File 2, Appendix A, and in Supplemental File 1.
We computed YLL by multiplying deaths at each age by
the reference standard life expectancy at that age, based
on the lowest age-specific death rates recorded and without
TABLE 3
Baseline cost data for the evaluation of the HARSP, in the communes of Pétionville, Carrefour, and Croix-des-Bouquets, West Department,
Haiti, 2014–2015
Item Units Unit value Sources
PEP
Basic vaccine dose (including administration)* $/dose 14.45
Material costs (needles, swabs, etc.) $/dose 0.12 Knobel and others12
Overhead costs per visit $/visit 0.61 Knobel and others12
Tissue-culture vaccine $/dose 12.20 Knobel and others12
Cold-chain $/dose 0.05 Acharya and others22
Cost per outpatient visit† $/outpatient 1.47 WHO-Choice23
Injections/doses per patient N 5 Poxvirus and Rabies Branch
Vaccine doses per visit N/visit 1 Recommendations
RIG‡ $ 134.15 Knobel and others12
PEP treatment paid for by the government (%) (0, 50, 100) Range used for estimates
Surveillance
Vehicle (motorcycle) (annual) $/vehicle 1,000 HARSP data
Maintenance (annual) $/vehicle 100 HARSP data
Animal capture equipment $/worker 800 HARSP data
Communications (mobile, radios, etc.) $/worker 200 Estimated
Rabies prevention supplies (annual) $/worker 500 HARSP data
Office rental§ $/year 4,000 Estimated
Utilities, supplies, etc. $/year 1,200 HARSP data
Personnel (annual) $/worker 3,300 HARSP data
Diagnostics
Equipment $/year 4,195 HARSP data
Equipment maintenance $/year 500 Estimated
Rabies reagents $/year 1,200 HARSP data
Supplies $/year 5,000 HARSP data
Personnel (annual) $/worker 6,006 HARSP data
Training‖
Teacher (year) $/training 1,487 HARSP data
Implementation (supplies, participants, etc.) $/training 301 HARSP data
HARSP = Haiti Animal Rabies Surveillance Program; PEP = postexposure prophylaxis; RIG = rabies immunoglobulin; WHO = World Health Organization. Additional cost data and details
on calculations are shown in the Supplemental File 2, Appendix A.
*Millien and others19 reported a stock of more than 15,000 does of human vaccine for PEP in stock (November 2014), from 20,000 Vero cell rabies vaccines for intramuscular administra-
tion donated by Brazil in 2013. Those authors also reported an annual use rate of about 8,000 human vaccine doses.
†WHO-Choice23 estimates: for a public facility. We used the average estimated costs for an outpatient visit of 1.47 (health center = $1.21, health center with beds = $1.50, primary-
level hospital = $1.71, and secondary-level hospital = $1.78) and adjusted the cost to 2014 US$.
‡The overhead and material costs from RIG were included in the basic PEP treatment of category III exposures.
§If owned, we estimated the cost per square meter for an office in the same area. Office rental and utilities costs were considered separately for laboratories and rabies surveillance.
If the office space was shared, we adjusted the value by multiplying it by the share of time dedicated to rabies.
‖These costs represent the costs of training prorated in 5 years. See Supplemental File 2, Appendix A, for details.
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age-weights or time preferences, for consistency with Global
Burden of Disease studies.25 We used the age distribution
of Haiti, assuming that Haiti had a similar rabies incidence
by age as Tanzania.11 We also considered incidence by
age data from Mexico26 and Ethiopia,27 but data were less
complete and the resulting age distributions of rabies were
similar to that of Tanzania.
Uncertainty and sensitivity. We conducted a multivari-
ate sensitivity analysis addressing the main sources of data
uncertainty: 1) share of PEP regimens paid by the govern-
ment, 2) probability that bite victims would seek medical
care, and 3) the probability that suspected rabid dogs were
actually rabid. In 2013, Brazil donated about 20,000 Vero
cell rabies vaccines for intramuscular administration19; how-
ever, a PEP program based on donations alone is unsus-
tainable and the share of PEP costs currently subsidized by
the government is uncertain. We thus present our results
considering that the government pays for 1) no PEP costs
(all is donated, including vaccine administration), 2) 50% of
PEP costs (transitional status), and 3) 100% of PEP costs
(self-sustaining status). We also show the variation of the
main results using cost as a continuous variable.
Second, there is substantial variation in bite victims’
health-care-seeking behavior. HARSP data show that 54%
of bite victims sought medical care in the study area.
However, a 2013 study in Pétionville estimated that 34%
of bite victims sought care and only 31% initiated rabies
vaccination.28 In contrast, 80% of rabies-exposed individ-
uals sought medical care, but less than 65% initiated PEP
in Tanzania.15 We used a range of 15–85% of bite victims
presenting to a health-care facility to account for this uncer-
tainty in the sensitivity analysis. We varied the share of PEP
regimens paid by the government (0%, 50%, and 100%),
the probability that bite victims would seek medical care
(baseline HARSP data: 54%, estimated range: 15–85%), and
the probability that suspected rabid dogs were actually rabid
(baseline HARSP data: 6.3%, estimated range: 1–36%; upper
bound was obtained from Hampson and others’ estimate
for Haiti).2
RESULTS
Table 4 shows the epidemiological parameters used in
the evaluation, based on field data collected by HARSP.
During 2014–2015, 54% of bite victims assessed by
HARSP were reported from medical facilities. The remaining
46% of bite victims were found through active community
bite investigations or direct reporting to HARSP from the
TABLE 4
Epidemiological and health-care-seeking behavior data from comparison scenarios for patients with suspected rabies exposure who sought
medical care or were identified through community bite investigations, Pétion-Ville, Carrefour, and Croix-des-Bouquets, West Department,
Haiti, 2014–2015
Scenarios Units NBCM HARSP HARSPr WHOr
Health-care-seeking behavior
Share of patients who seek medical care* % 54% 54% 54% 54%
Additional patients who seek medical care as a
result of the bite investigation†
% 0% 40% 46% 0%
Share who did not seek care, despite HARSP advice 6% 0%
Of patients who seek care, % that start PEP
Confirmed % 18% 100% 100% 100%
Probable % 44% 68% 100% 100%
Suspected % 41% 100% 100% 100%
Negative % 39% 78% 0% 100%
PEP treatment
PEP (recommended vaccine doses) N 5 5 5 5
Of those who start PEP vaccines, % compliance
Confirmed % 33% 78% 100% 100%
Probable % 33% 37% 100% 100%
Suspected % 33% 33% 100% 100%
Negative % 33% 33% 0% 100%
RIG N 0.82 0.82 0.82 0.82
Share of category III exposures % N/A N/A 82% 82%
Of those who get PEP vaccines, % receive RIG
Confirmed % 13% 11% 82% 82%
Probable % 13% 0% 82% 82%
Suspected % 13% 13% 82% 82%
Negative % 13% 13% 0% 82%
Fatal human rabies infections‡ N 14 3 0 8
Confirmed N 6 0 0 3
Probable N 6 3 0 4
Suspected N 2 0 0 1
Negative N 0 0 0 0
Treatment setting
Outpatient visits N 5 5 5 5
HARSP = Haiti Animal Rabies Surveillance Program; HARSPr = HARSP recommendations for implementation of the program and rabies treatment; NBCM = no bite case management;
PEP = postexposure prophylaxis; RIG = rabies immunoglobulin; WHO = World Health Organization; WHOr = WHO recommendations for rabies treatment.
*Percentage of patients, out of the total sample of patients who were reported to HARSP (by any means), that were reported to HARSP from a medical institution in Haiti.
†Share of patients who seek medical care as a result of active bite investigations following a bite report from a suspected rabid dog. A retrospective study of suspected rabies exposures
in Pétionville, Haiti, in 2013 (Etheart and others, unpublished data) showed that 6% of suspected rabies exposures did not seek medical care despite HARSP advice. The NBCM scenario
did not include active bite investigations, so the percentage is zero. WHO does not currently recommend active bite investigation in their guidelines.
‡Fatal human infections were estimated based on people’s medical care–seeking behavior and the probability that the bite victim was exposed to rabies. We assumed that any patient
who received PEP treatment did not develop rabies, independent of compliance with PEP schedules.
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victim. These individuals may have never sought medical
care without HARSP. A retrospective study showed that 6%
of bite victims did not seek medical care in 2015 despite
HARSP advice to do so.29
The costs of animal surveillance by programmatic sce-
nario are shown in Table 5. Dog investigations in 2014
(N = 778) resulted in 70 confirmed and 36 probable rabid
dogs, and in 60 confirmed and 60 probable rabid dogs in
2015 (N = 1,657). These investigations resulted in 45 imme-
diately euthanized dogs in 2014 and 47 in 2015 (Supple-
mental File 2, Appendix A). Dog investigations occasionally
occurred beyond the limits of the three communes of the
West Department.
Table 6 shows that HARSP substantially reduced the
burden from rabies in the area of implementation. Among
the 837 people reported to HARSP in 2014, we estimated
11 human deaths averted (14 under NBCM scenario to
three deaths with HARSP compared), and 654 years of life
gained (YLG) (832 YLL under NBCM to 178 with HARSP).
For 2015, we estimated a total of nine human deaths
averted among the 1,373 people assessed by HARSP (fatal
rabies: 11 NBCM, two HARSP) and 535 YLG (YLL: 654
NBCM, 119 HARSP). Partly from a substantial increase in
the number of identified bite victims and the associated
PEP costs, independent from how much the government
paid, the overall costs of the rabies prevention were always
higher with HARSP compared with the scenario without
HARSP (NBCM) (Table 6, 2014 [A] NBCM, vaccine doses:
290, costs: $15,988–$22,600; [B] HARSP, vaccine doses:
1,150, costs: $39,531–$64,750; 2015 [A] NBCM, vaccine
doses: 477, costs: $16,025–$26,976; [B] HARSP, vaccine
doses: 1,794, costs: $39,568–$80,290). However, HARSP
had a considerably bigger impact in reducing human rabies,
with approximately 11 deaths averted in 2014 and nine in
2015 compared with the NBCM scenario. Ultimately, HARSP
was always more cost-effective than NBCM (2014: NBCM:
$5,980–$8,453 per death averted, $101–$142 per YLG;
HARSP: $2,891–$4,735 per death averted, $49–$80 per
YLG; 2015: NBCM: $7,298–$12,284 per death averted,
$123–$207 per YLG; HARSP: $3,534–$7,171 per death
averted, $59–$121 per YLG).
We found substantial variation in the expected number
of human deaths from rabies when varying the share of
patients who seek medical care (Figure 2), particularly for
NBCM and WHOr. Figure 2A–C shows how these results
change by the probability that the offending dog (suspected
rabid) was actually rabid. Because HARSP included dog bite
investigations, changing the probability that the offending
dog was rabid did not substantially affect the expected
number of deaths from rabies for the HARSP scenarios.
Figure 3 shows a multivariate sensitivity analysis of the
estimated cost per death averted, varying the share of
patients bitten by a suspected rabid dog who seek medical
care and the share of PEP costs paid for by the govern-
ment. The share of bite victims who seek medical care gen-
erated the greatest variation in results, especially for NBCM
and WHOr. These two scenarios were also considerably
affected by the share of suspected rabid dogs that actually
have rabies. The results for WHOr also noticeably varied by
the share of PEP costs paid by the government, because
all exposures are treated as a suspected rabies exposure.
Because HARSP included active community bite investiga-
tions, the program reached bite victims who did not seek care
and offered PEP based on actual risk. Consequently, HARSP
cost-effectiveness estimates were not greatly affected by
changes in people’s health-care-seeking behavior or in the
probability that suspected rabid dogs had rabies.
DISCUSSION
HARSP substantively reduced the risk of human rabies
death compared with the scenario without the program
(NBCM) (additional annual averted deaths: 11 in 2014, nine
in 2015; YLG: 654 in 2014 and 535 YLG in 2015). Imple-
menting HARSP imposed a higher economic burden to the
government of Haiti than the NBCM scenario (2014 NBCM:
$15,988–$22,600; HARSP: $39,531–$64,750; 2015 NBCM:
$16,025–$26,976; HARSP: $39,568–$80,290). The cost
differences were largely explained by HARSP’s active bite
investigation component, which identified an additional
40% bite victims, some of which initiated PEP at an addi-
tional cost compared with non-HARSP scenarios. Costs
also increased under HARSP scenarios due to improved
PEP compliance. Dog bite investigations helped determine
categories of dog rabies infection (i.e., confirmed, proba-
ble, suspected, and negative), which allowed for a more
targeted use of PEP regimes for dog bite victims through
communication of rabies risk based on case investiga-
tions. Under HARSP, there was higher compliance of full
PEP regimes among confirmed and probable dog rabies
exposures (78% and 37%, respectively) compared with
suspected rabies exposures (33% compliance). This improve-
ment in PEP compliance came at a slight cost increase of
PEP per exposed patient who initiated treatment (NBCM:
$37.6, HARSP: $38.8).
Rabies exposures constitute only a small proportion of
dog bites in Haiti; therefore, there are potential savings in
the administration of PEP regimes derived from delaying
follow-up vaccination of bite victims based on a skilled
animal assessor’s evaluation of the offending dog. The
TABLE 5
Summary of estimated annual costs of the dog surveillance pro-
gram by evaluation scenario (2014 U.S. dollars), Pétion-Ville, Car-
refour, and Croix-des-Bouquets, West Department, Haiti,
2014–2015
Animal rabies diagnostic facility NBCM HARSP
Animal rabies diagnostic facility $5,184 $12,920
Capital costs 1,787 4,195
Operational costs 1,435 6,935
Personnel 1,962 1,790
Animal rabies surveillance program $10,804 $24,823
Capital costs 44 1,572
Operational costs* 6,237 8,263
Personnel 4,488 14,988
Required trainings HARSP $0 $1,788
Operational costs 0 301
Personnel 0 1,487
Total annual costs $ 15,988 $ 39,531
HARSP = Haiti Animal Rabies Surveillance Program; NBCM = no bite case manage-
ment. The full list of items considered for cost calculations of the surveillance program
are shown in the Supplemental File 2, Appendix A. We used constant dollars (no inflation)
and a discount rate of 3% for capital investments.30
*There were negligible differences in the operational costs of the HARSP program due
to differences in the number of dogs that were euthanized in 2014 and 2015. HARSP
euthanized 45 dogs in 2014 and 47 in 2015 (see Supplemental File 2, Appendix B). The
number of dogs under observation varied substantially from 2014 (N = 453) to 2015
(N = 1,189), but dogs put in observation have no additional costs to the government.
1312 UNDURRAGA AND OTHERS
government of Haiti has not formally adopted a policy to
delay treatment based on a quarantine or testing outcome,
and WHO recommendations do not include delaying PEP.
While not considered in this economic evaluation, delaying
follow-up PEP in relatively low-risk exposure scenarios
where the animal is available for assessment by an experi-
enced animal assessor (∼60% of potential exposures in
HARSP) could reduce the costs of PEP while posing a
negligible risk upon the exposed individual. The ideal of
zero wastage of PEP on nonexposed individuals is unlikely,
if not impossible, in dog rabies–endemic countries.
When considering both the costs and health outcomes,
HARSP was more cost-effective than NBCM (2014: NBCM:
$5,980–$8,453 per death averted, HARSP: $2,891–$4,735
per death averted; 2015: NBCM: $7,298–$12,284 per death
averted, HARSP: $3,534–$7,171 per death averted), and the
program has potential for improvement, as suggested by
the HARSPr scenario results. From a societal perspective,
that is, considering all costs and benefits irrespective of
who pays and benefits from the intervention, the program
would result in net benefits for the society as long as an
additional year of life is valued at more than $121.
The effectiveness of HARSP may be even greater than
estimated for at least three reasons: first, the rapid removal
of rabid animals from the community may have reduced local
dog-dog and dog-human rabies transmission, an effect that
would be partly unaccounted for in this evaluation. In 2014
alone, 51 confirmed or probable rabid dogs were removed
from these three communities. If we assumed that half of
these dogs removed from the community bit just one addi-
tional person had HARSP investigators not been present to
euthanize or confine the dog, we would expect about four
additional human deaths when considering the parame-
ters presented here. Routinely confining and observing
biting dogs, independent of whether they are rabid or not,
very likely resulted in fewer bite incidents and, as a conse-
quence, a lower demand for PEP from suspected rabies
exposures, although we did not consider this potential ben-
efit in our cost estimates.
Second, the program may have decreased the risk of
acquiring rabies beyond the three communes assessed,
as dog investigations occasionally occurred beyond the
three communes in the West Department. A previous evalu-
ation of HARSP10 (2013–2015) had already established
TABLE 6
Main cost-effectiveness outcomes from the implementation of the HARSP initiated in Pétionville, Carrefour, and Croix-des-Bouquets
communes, West Department, Haiti, 2014–2015
Program indicators (annual) Units
NBCM HARSP HARSPr WHOr
[A] [B] [C] [D]
Evaluation year 2014
Effectiveness of the intervention
Fatal human rabies infections N 14 3 0 8
YLL due to premature death* N 832 178 0 475
PEP vaccine doses administered N 290 1,150 1,290 2,260
Costs of the intervention (including biologics)
Government pays no PEP costs (all donated) US$ 15,988 39,531 39,531 15,988
Government subsidizes 50% of PEP costs (transition) US$ 19,294 52,140 60,477 52,682
Government pays 100% of PEP costs (self-sustaining) US$ 22,600 64,750 81,422 89,376
Cost-effectiveness indicators
Average cost per human rabies death averted
Government pays no PEP costs (all donated) US$/death 5,980 2,891 2,371 1,843
Government subsidizes 50% of PEP costs (transition) US$/death 7,216 3,813 3,627 6,074
Government pays 100% of PEP costs (self-sustaining) US$/death 8,453 4,735 4,883 10,304
Average cost per LYG
Government pays no PEP costs (all donated) US$/LYG 101 49 40 31
Government subsidizes 50% of PEP costs (transition) US$/LYG 121 64 61 102
Government pays 100% of PEP costs (self-sustaining) US$/LYG 142 80 82 173
Evaluation year 2015
Effectiveness of the intervention
Fatal human rabies infections N 11 2 0 7
YLL due to premature death N 654 119 0 416
PEP vaccine doses administered N 477 1,794 1,225 3,707
Costs of the intervention (including biologics)
Government pays no PEP costs (all donated) US$ 16,025 39,568 39,568 16,025
Government subsidizes 50% of PEP costs (transition) US$ 21,501 59,929 59,988 77,822
Government pays 100% of PEP costs (self-sustaining) US$ 26,976 80,290 80,409 139,618
Cost-effectiveness indicators*
Average cost per human rabies death averted
Government pays no PEP costs (all donated) US$/death 7,298 3,534 2,998 2,586
Government subsidizes 50% of PEP costs (transition) US$/death 9,791 5,353 4,546 12,560
Government pays 100% of PEP costs (self-sustaining) US$/death 12,284 7,171 6,093 22,534
Average cost per LYG
Government pays no PEP costs (all donated) US$/LYG 123 59 50 44
Government subsidizes 50% of PEP costs (transition) US$/LYG 165 90 77 211
Government pays 100% of PEP costs (self-sustaining) US$/LYG 207 121 103 379
HARSP = Haiti Animal Rabies Surveillance Program; LYG = life-year gained; NBCM = no bite case management; PEP = postexposure prophylaxis; WHOr = WHO recommendations for
rabies treatment; YLL = years of life lost.
*A lower cost-effectiveness ratio indicates that the program achieves the same health outcome at a lower average cost.
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a much higher rabies burden in Haiti than the reported
annual average of four dog and seven human rabies cases
(2009–2012).17,31 Our results confirm that rabies burden
is substantially underrecognized in Haiti. Consistently, a
modeling study of rabies burden estimated 130 annual
deaths in Haiti.2 If the rabies burden is proportional to the
human population, we would expect ∼14 deaths in the
three communes where HARSP was implemented (popu-
lation32: 1,085,817), which is what we obtained in the
NBCM scenario for 2014 (Table 6, [A]). Using the same
criteria, we would expect an average of ∼48 annual
deaths in the West Department under the NBCM (popula-
tion32: 3,845,600). About 15 additional dog-mediated
human deaths from rabies were averted by HARSP in the
West Department, considering the overall effects of the
program and assuming that half of the rabid dogs
removed from the community would have bitten just one
additional person. That represents a potential 31%
decrease in the probability of dying from rabies in the
West Department, simply by having a trained force of vet-
erinary professionals available to respond to reports of sus-
pected rabid animals (Supplemental File 2, Appendix B).
Dividing by the total population in the West Department, the
costs for this potential risk reduction were US$0.02 per per-
son, that is, equivalent to ∼0.03% of the annual public and
private health expenditures per person in Haiti (US$77.00,
water and sanitation excluded).33
Third, the estimated improvement in cost-effectiveness of
the HARSP scenario would be conservative if the observed
increase in vaccination coverage in recent years decreased
enzootic transmission. Haiti has supported dog mass vac-
cination programs consistently for the past 5 years. The
results from a capture-recapture study (CDC, unpublished
data) after the dog vaccination campaign of July 2014–April
2015 suggest that about 40% of the dog population in
Haiti’s West Department was vaccinated against rabies.
While the impact of low-level vaccination coverage on dog
rabies transmission is not well established, we observed a
reduction in the proportion of observed dogs confirmed to
be rabid in 2015 compared with 2014.
As with many developing countries, the Haitian govern-
ment has limited resources that preclude the implementa-
tion of effective mass dog vaccination campaigns at this
time.17 Reactive PEP-based solutions may reduce human
rabies, as has happened, for example, in Vietnam.34 How-
ever, growing human and dog populations will likely result
in ever-increasing costs, thus making this strategy nonsus-
tainable.14 Health expenditures as a share of gross domes-
tic product have increased in Haiti in the past decade from
4.4% in 2005 to 7.6% in 2014,33 but policy-makers face
competing demands. Additional strategies of rabies preven-
tion, not included in HARSP, may also help to optimize the
use of limited resources. For example, child education pro-
grams and awareness campaigns may reduce rabies expo-
sures and increase PEP use.8 Using intradermal regimes
instead of intramuscular regimes of PEP administration
could reduce the direct cost of vaccines by 60–80%.1,18
There is limited evidence that dog population management
methods are effective at reducing the rates of dog rabies,
although theoretically they could support vaccination cam-
paigns; however, these programs can be very costly.35–37
Animal surveillance and control are usually in the realm of
the ministry of agriculture, but a substantial share of the
costs from rabies exposures fall on the ministry of health,
which makes coordinating rabies prevention challenging.
An intersectoral program, such as HARSP, can partially
overcome these limitations by providing a more accurate
FIGURE 2. Two-way sensitivity analysis of the total fatal human
rabies infections in the area of implementation of HARSP in 2014
by share of patients who seek medical care (%), and probability
that a person bitten by a dog was exposed to rabies; (A) 1%,
(B) 6.3% (estimate from HARSP), and (C) 36%(based on Hampson
et al.’s estimates for Haiti). The figure shows results for 2014;
results for 2015 are shown in the Supplemental File 2, Appendix B.
A, B, and C show how the estimate for total fatal human rabies
infections in the area of implementation of HARSP vary by the
share and patients who seek medical care and the probability
that the offending dogs among the HARSP population were actu-
ally rabid. HARSP = Haiti Animal Rabies Surveillance Program;
HARSPr = Haiti Animal Rabies Surveillance Program (HARSP)
recommendations for implementation of the program and rabies
treatment; NBCM = no bite case management; WHO = World
Health Organization; WHOr = World Health Organization recom-
mendations for rabies treatment.
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estimate of rabies exposures in humans and prevalence in
animals, and by encouraging both sectors to work together
in a very practical way.
Our study has limitations. First, there is substantial uncer-
tainty in the share of individuals potentially exposed to
rabies who seek medical care. HARSP data suggested that
54% of potentially exposed individuals sought medical care
in the study area, but this figure could be lower. Health-
care-seeking behavior probably varies by rabies awareness,
competing diseases, education, accessibility to health care,
and travel costs, among other factors. Our sensitivity analy-
sis suggests that the estimates for HARSP were not sub-
stantively affected by health-care-seeking behavior. Active
community bite investigations resulted in a substantial
increase in health-care-seeking behavior, which did not
occur under a NBCM or WHO scenario. But the true num-
ber of bite victims who did not seek care remains unknown.
Second, we evaluated an intervention in three communes
with closely monitored training and implementation of the
diagnostic and surveillance components by international
FIGURE 3. Multivariate sensitivity analysis: average cost per death averted (2014 US$/death) by share of patients who seek care (%), proba-
bility that a person bitten by a dog was exposed to rabies, and share of PEP costs paid by the government. The evaluation corresponds to
year 2014. The estimated probabilities that a person bitten by a dog was exposed to rabies (1%, 6.3%, and 36%) were based on a plausible
lower bound, data from HARSP project’s dog investigations (average for 2014–2015), and estimates by Hampson and others’ for Haiti,2
respectively. The share of patients who seek medical care was based on HARSP data (54%), and an illustrative range of 15–85%. HARSPr =
Haiti Animal Rabies Surveillance Program (HARSP) recommendations for implementation of the program and rabies treatment;
NBCM = no bite case management; PEP = postexposure prophylaxis; WHOr = World Health Organization recommendations for
rabies treatment.
1315COST-EFFECTIVENESS OF HUMAN RABIES PREVENTION IN HAITI
partners. The escalation of this intervention to a national
level may not necessarily result in the same quality of oper-
ation, due to differences in accessibility, health-care quality,
public infrastructure, funding, and others, among the differ-
ent departments in Haiti.
Third, there were limited data about the burden of rabies
in Haiti, which restricts the generalizability of our findings.
For example, to estimate the YLL, we estimated the age
distribution assuming that Haiti has similar incidence rates
of rabies by age as Tanzania.11 The estimated age distribu-
tion from reported rabies deaths in Ethiopia27 was similar to
Tanzania, and slightly skewed toward older age if com-
pared with the distribution of reported dog-bite injuries in
Mexico.26 Had we used the age distribution from Mexico,
the estimated YLL would have been slightly higher in all
scenarios, making HARSP look more favorable. Despite
limited rabies surveillance data from Haiti, our estimates
for rabies in the NBCM scenario are largely consistent with
those of Hampson and others.2
Fourth, because we did not collect economic data prior
to the implementation of HARSP, we used a cost structure
for the animal rabies surveillance and diagnostics program
under the WHOr and NBCM scenarios that was similar to
that of HARSP, but we adjusted costs based on preexisting
rabies diagnostic and surveillance activities, personnel, and
equipment. Where necessary, we made conservative esti-
mates of NBCM costs, to avoid overestimating the incre-
mental cost-effectiveness ratios of HARSP.
Last, we only included costs per outpatient visits and
assumed that no bite victim was hospitalized, as the evi-
dence suggests that only a few episodes of rabies, if any,
are hospitalized,2 probably because once symptoms appear
the disease is almost always fatal.24 But we cannot confirm
that this was always the case, due to limitations in reporting,
surveillance, and laboratory capacity, and to the similarity of
clinical symptoms of rabies with other diseases, such as
cerebral malaria.38 Our results confirmed that rabies is
underreported in Haiti, and our estimated deaths under the
HARSP scenario seem reasonable and in agreement with
previous estimates of rabies burden in the country.2,10
Overall, HARSP substantially reduced the expected risk
of rabies transmission, resulting in more averted deaths
and YLG, and was more cost-effective than the scenario
without HARSP (NBCM). However, implementing and oper-
ating HARSP was more costly to the government than not
having the program largely due to active community investi-
gation components and the associated higher PEP costs.
Additionally, HARSP helped to establish a better estimate
of the disease burden of rabies in the three communes
where the program operated, reduce the number of expected
deaths from rabies exposures, and determine categories of
dog rabies infections (i.e., confirmed, probable, suspected,
and negative) for a more targeted use of PEP regimes.
Improved surveillance data from HARSP can be used to
track rabies disease burden, evaluate intervention programs
and strategies, and focus on disease elimination. In sum,
HARSP offers a cost-effective human rabies prevention solu-
tion for countries transitioning from reactive to preventive
strategies (i.e., comprehensive dog vaccination). This eval-
uation is intended to provide policy-makers, donors, and
the public affected by dog rabies with evidence to inform
decisions about rabies prevention and program replication.
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